Alyesa Organa
The Hidden Architect
SPECIAL FEATURES
The XBC-9 "Bloodweave" is a field-deployable synthetic hemofluid developed by XeroCorp Technologies for frontline trauma response and extended deployment scenarios. Designed to replicate the functions of natural blood while improving upon its limitations, Bloodweave uses suspended nanites that analyze host physiology, replicate themselves in situ, and generate a sustained supply of synthetic blood volume.
Upon administration—either intravenously or via emergency auto-injection—the compound adapts to the recipient's circulatory system, providing immediate oxygen saturation, coagulation, and early immune filtration. Each vial includes a nanite population large enough to regenerate up to 120% of baseline blood volume, making it ideal for mass trauma scenarios or deep-space operations far from advanced medical infrastructure.
While exceptionally effective in standard conditions, Bloodweave is not without limitations. Its nanites are highly vulnerable to electromagnetic fields if not properly shielded, and the compound loses integrity when stored in non-regulated environments. For this reason, it is typically issued only to XeroCorp medical teams or authorized contractors outfitted with compliant cryo-storage units.
Though officially restricted to internal use, rumors persist of off-market variations—often stripped of self-replication protocols—being traded among mercenary units, paramilitary crews, and deep-space salvage outfits.
- Self-replicating hemofluid
- Embedded nanites for clotting, immune response, and pathogen screening
- Adaptive oxygenation protocols
- Transfusion-compatible with most humanoid species
- Functional in both IV and direct injection formats
- Self-replicating formula—reduces volume requirements during emergency deployment
- Nanite-assisted clotting and immune screening
- Multi-species compatibility for wide application
- Breaks down in high-acid or corrosive environments
- Vulnerable to EMP disruption
- Requires cold storage for long-term viability
The XBC-9 "Bloodweave" is a field-deployable synthetic hemofluid developed by XeroCorp Technologies for frontline trauma response and extended deployment scenarios. Designed to replicate the functions of natural blood while improving upon its limitations, Bloodweave uses suspended nanites that analyze host physiology, replicate themselves in situ, and generate a sustained supply of synthetic blood volume.
Upon administration—either intravenously or via emergency auto-injection—the compound adapts to the recipient's circulatory system, providing immediate oxygen saturation, coagulation, and early immune filtration. Each vial includes a nanite population large enough to regenerate up to 120% of baseline blood volume, making it ideal for mass trauma scenarios or deep-space operations far from advanced medical infrastructure.
While exceptionally effective in standard conditions, Bloodweave is not without limitations. Its nanites are highly vulnerable to electromagnetic fields if not properly shielded, and the compound loses integrity when stored in non-regulated environments. For this reason, it is typically issued only to XeroCorp medical teams or authorized contractors outfitted with compliant cryo-storage units.
Though officially restricted to internal use, rumors persist of off-market variations—often stripped of self-replication protocols—being traded among mercenary units, paramilitary crews, and deep-space salvage outfits.
Out Of Character Info
Intent:
: To create a self-replicating synthetic blood product for use in trauma recovery, emergency field care, and long-duration medical operations under the exclusive control of XeroCorp Technologies and its authorized partners.
Technical Information
Affiliation:
Alyesa Organa, XeroCorp Technologies and authorized partners.
Modular:
No
Material:
Nanite-seeded synthetic hemofluid, oxygen-reactive biochain compounds
